ARM and ISCT collaborating to advance regenerative medicine therapies
A memorandum of understanding between the Alliance for Regenerative Medicine (ARM) and the International Society for Cellular Therapy (ISCT) has formalized their collaboration on specific projects aiming to support the advancement of potentially life-saving treatments.
The Alliance for Regenerative Medicine (ARM; WA, USA), the international organization representing the gene and cellular therapies and the regenerative medicine sector, and the International Society for Cellular Therapy (ISCT; WA, Canada), a global association driving the translation of scientific research to deliver innovative cellular therapies to patients, announced today they have entered into a memorandum of understanding.
Signed by ISCT President Massimo Dominici and ARM Managing Director Morrie Ruffin, the memorandum of understanding describes the first formal collaboration between ARM and ISCT. “ARM and ISCT are united by a common goal of advancing innovative cell therapies,” stated Morrie Ruffin. “Our further collaboration on various projects streamlines efforts to bring potentially life-saving treatments to patients with current unmet medical needs.”
According to the terms of the memorandum, ARM and ISCT will establish an ISCT-ARM joint committee to advance potential projects.Such collaborative project will include the formation of and participation in an International Standards Coordinating Body; working group activities related to ISO standards for cell therapy and other regenerative medicines; support for international communication as well aseducation initiatives related to cell therapy and participation in each organization’s conference programs.
“In recent years, the cell therapy field has expanded exponentially. This is in terms of scientific discovery, clinical results and investment, all of which generate enormous opportunity for patients as well as the industry,” explained Massimo Dominici. “This potential requires a consensus and collaboration from the top organizations representing the cell therapy community. As a result, it will be critical for ISCT and ARM to work closely together to monitor and drive the cell therapy sector to realize its full potential in delivering lifesaving and changing treatments to patients.”